

























































Transport of Lipophilic Anti-Tuberculosis Drug Benzothiazone-043
in Ca3(PO4)2 Nanocontainers
David Rudolph,[a] Natalja Redinger,[b] Ulrich E. Schaible,*[b] and Claus Feldmann*[a]
Abstract: 1,3-Benzothiazin-4-one-043 (BTZ043) is a novel anti-
mycobacterial agent for tuberculosis (TB) therapy with highly
hydrophobic properties. In order to enhance local drug
concentrations by improved administration and delivery to
the site of the mycobacterial infection, we suggest BTZ043/
Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers made via a micro-
emulsion approach for drug delivery (Toc: tocopherol; ds:
dodecylsulfate). Based on our concept, the surfactant of the
microemulsion itself is used to stabilize the droplet phase by
interaction with Ca2+, followed by the formation of an
inorganic Ca3(PO4)2 sphere wall in one-pot reaction. Toco-
pherol (vitamin E) was used as biocompatible droplet phase
of the microemulsion to dissolve the highly lipophilic BTZ043.
According to electron microscopy and electron spectroscopy,
the resulting BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers
exhibit an outer diameter of 28�8 nm and a sphere wall of
4�1 nm. The inner cavity, 18�7 nm in diameter, is loaded
with BTZ043 with a concentration of 30.5 μg/mL. First in vitro
tests with murine bone marrow derived macrophages
infected with Mycobacterium tuberculosis show promising
antibiotic activity of the BTZ043/Toc@Ca(ds)2@Ca3(PO4)2
nanocontainers.
1. Introduction
Tuberculosis (TB) is the most prevalent infectious disease
worldwide with 1.45 million deaths and 10 million new cases in
2019.[1] Antimicrobial multi-resistance is an additional severe
threat as illustrated by 600.000 new TB cases being mono-
resistant to rifampicin and 81% of those additionally to
isoniazid, two of the most important first-line anti-TB drugs.[1]
Today’s search for promising drugs, e.g., via combinatorial
chemistry and high-throughput screening, results in a con-
current shift of the emerging candidates to higher molecular
weight and lower hydrophilicity.[2] Concepts to combat TB and
anti-bacterial resistance, therefore, not only need to explore
novel anti-microbial agents, but also to make suitable drug
carriers available. Thus, efficient strategies for lipophilic anti-
biotics to be transported in aqueous media and to cross
different biological barriers are required, in order to reach
sufficient concentrations of the antibiotics at the site of
infection without causing adverse effects in unrelated organs.[1,3]
Mycobacteria are facultative intracellular pathogens proliferat-
ing within phagosomes of macrophages and related phago-
cytes. Therefore, biological barriers include the host cell
membrane, the phagosomal membrane, the inner and outer
membrane of the pathogenic agent, Mycobacterium tuberculosis
(M.tb.), as well as the inflammatory tissue reaction sequestering
the sites of infection, the granuloma.[3,4]
1,3-Benzothiazin-4-ones (BTZs) are a new class of anti-
mycobacterial agents that kill M.tb. by inhibition of the enzyme
decaprenylphosphoryl-β-d-ribose 2’-epimerase and by abolish-
ing the decaprenylphosphoryl arabinose formation.[5] Among
these 1,3-benzothiazin-4-ones, BTZ043 is currently the most
advanced agent in regard of the progress of clinical studies.[6]
Dosage schemes of lipophilic BTZ043 comprise powder aerosols
for lung inhalation or tablets for gastrointestinal absorption.
Powder aerosols, however, exhibit broad size distribution with a
significant fraction of large particles and aggregates that do not
enter the deep lung and bronchioli.[7] Since M.tb.-infection is
primarily a lung infection, gastrointestinal absorption is less
effective due to inefficient transport to the distant lung.[8]
Efficient drug delivery concepts are therefore still highly
requested. Although nanocarriers were intensely discussed for
improved lung targeting,[9] they were rarely applied for tuber-
culosis and so far not reported for BTZ043.
Nanoparticle-based delivery systems for lipophilic drugs, in
general, often suffer from uncontrolled drug leakage and
aggregation, limited cell uptake, high material complexity,
unexpected toxicity and hypersensitivity, damage of cell
membranes, inadequate drug loading, and/or poor stability in
blood.[1b,8a,b,10] In this regard, novel nanocarrier concepts are also
highly interesting for an efficient transport and delivery of
lipophilic TB antibiotics. Based on our studies related to
microemulsion-made hollow nanospheres,[9d,11] we here describe
the synthesis of Ca3(PO4)2 nanocontainers filled with lipophilic
BTZ043 as well as the characterization of the hollow nano-
spheres, including a first evaluation of the antibiotic activity.
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2. Results and Discussion
2.1. Synthesis and colloidal properties of BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers
BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers were prepared
using the micellar droplets of a microemulsion as a template.
Hence, a colloidally stable oil-in-water microemulsion (o/w-ME)
was required. Since the most common lipophilic solvents to
establish microemulsion systems (e.g., hexane, octane, toluene)
are of limited biocompatibility, we have used tocopherol
(Figure 1a). Tocopherol–also called vitamin E–is present in many
edible oils and easily metabolized by mammals. Tocopherol-
based microemulsion systems have been rarely reported by
now and were only recently applied for subcutaneous
delivery.[12] To stabilize the tocopherol droplet phase in water,
sodium dodecylsulfate (SDS) was applied as anionic surfactant
in combination with n-butanol as the co-surfactant (Figure 1a).
Notably, an increase in the common co-surfactants, n-pentanol
and n-hexanol in combination with tocopherol, only resulted in
highly viscous gelatinous phases. In contrast, microemulsions
with n-butanol and a SDS :n-butanol ratio around 1 :2 turned
out to be highly stable. Thus, optically transparent micro-
emulsions were obtained after equilibration that show a slight
yellow color originating from tocopherol (Figure 1a).
After establishing the microemulsion, BTZ043 as the active
agent was dissolved in the tocopherol droplets (Figure 1b). The
presence of BTZ043 is qualitatively already indicated by the
characteristic red color. Such drug-loaded microemulsion
droplets, however, are of limited stability in aqueous suspension
since the surfactant is detached from the surface due to particle
collision in suspension, which results in uncontrolled agglomer-
ation on a timescale of about 30 min. Drug-loaded micro-
emulsion droplets are known to be even less appropriate for
physiological use due to their low stability in cell culture media
and blood, uncontrolled drug leakage and aggregation of the
lipophilic drug, unexpected cellular toxicity and hypersensitivity
as well as damaging of cell membranes.[3,8c,13] Therefore, the
BTZ043/tocopherol droplets were stabilized by an inorganic
Ca3(PO4)2 shell (Figure 1c,d). Beside the stabilization of the
lipophilic droplet phase, the addition of Ca2+ was chosen for
several reasons. On the one hand, Ca(ds)2 (ds: dodecylsulfate) as
well as Ca3(PO4)2 are insoluble in water at neutral pH. On the
other hand, calcium and phosphate can be considered as less
harmful and highly biodegradable. To control the synthesis and
formation of the inorganic nanocontainer, first of all, a solution
of Ca(Ac)2 was added to the microemulsion system. By ionic
interaction Ca2+ coordinates to the sulfate groups of ds and
reduces the thermal motion of the surfactant (Figure 1c). After
equilibration, an aqueous solution of Na2(HPO4) was slowly
added, which initiates slow formation of a Ca3(PO4)2 shell
(Figure 1d). The formation of the Ca3(PO4)2 shell is optically
indicated by the brightening of the BTZ043-induced red color.
This color change is driven by the reflection of daylight from
the outer colorless Ca3(PO4)2 shell (Figure 1d).
The course of the reaction and specifically the modification
of the particle surface can be also followed by measuring the
Zeta potential (Figure 2a). The ds-stabilized microemulsion
exhibits a highly negative charge of   95 to   100 mV at pH 5 to
12. After addition of Ca2+, the surface charge is much less
negative (  35 to   45 mV). Now, there is also a stronger
influence of the pH on the surface charge, which can be
ascribed to the protonation/deprotonation of H2O molecules
coordinated to Ca2+ on the side of the solution. Moreover, the
cation termination results in a precipitation of the nanoparticles
after some minutes (Figure 1c), whereas the ds-stabilized micro-
emulsion and the final nanocontainers remain colloidally stable
over several weeks (Figure 1b,d). Subsequent to the formation
of the Ca3(PO4)2 shell, the BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nano-
containers do not show considerable change of the surface
charge (  35 to   55 mV) in comparison to BTZ043/Toc@Ca(ds)2
(  35 to   45 mV) However, the course of the surface charge
with highest negative charging at pH 12 and a continuous
decrease of the charge at more acidic pH is characteristic for
phosphates[14] and fits with calcium phosphate as outer shell of
the nanocontainers (Figure 2a). After purification, colloidally
highly stable suspensions of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2
nanocontainers were obtained. The yellow suspensions do not
Figure 1. Scheme illustrating the synthesis of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers: a) o/w-Microemulsion with tocopherol as lipophilic droplet
phase, ds as the surfactant and n-butanol as the co-surfactant; b) Microemulsion with a saturated solution of BTZ043 in tocopherol as lipophilic droplet phase;
c) Stabilization of droplet phase by formation of Ca(ds)2; d) Formation of the outer inorganic Ca3(PO4)2 shell.
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show any sedimentation over a timescale of several weeks.
Finally, dynamic light scattering (DLS) indicates a mean hydro-
dynamic particle size of 30�6 nm (Figure 2b), which is well in
agreement with the mean particle size obtained from statistical
evaluation of >150 particles on scanning electron microscopy
(SEM) images (27�4 nm).
2.2. Composition of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2
nanocontainers
The chemical composition of the as-prepared BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers was characterized by X-ray
powder diffraction (XRD), Fourier-transformed infrared spectro-
scopy (FT-IR), thermogravimetry (TG), and elemental analysis
(EA) (Figure 3). According to XRD, the nanocontainers are
amorphous for the most part, which is expected for metal
phosphates prepared at ambient temperature.[15] Two very
weak and broad peaks nevertheless indicate the presence of
Ca10(PO4)6(OH)2 (Figure 3a). FT-IR predominately confirms the
presence of phosphate (ν(P=O): 1150–1050 cm  1) and ds
(ν(S=O): 1300–1200 cm  1) (Figure 3b). The vibrations of BTZ043
are less characteristic due to its low concentration relative to
tocopherol and Ca3(PO4)2 and due to partial overlay with other
vibrations. Finally, EA allows determining the C/H/N/S contents
and results in 40.7% C, 6.2% H, 0.3% N and 3.6% S. Hereof, the
N content is indicative for BTZ043, so that a BTZ043 load of
3.1 mg per 100 mg for the BTZ043/Toc@Ca(ds)2@Ca3(PO4)2
nanocontainers can be deduced. Total organics combustion
determined by TG shows two step decomposition with a first
step at 50–150 °C (12 wt-%) and a second step at 150–500 °C
(63 wt-%) (Figure 3c). The first decomposition can be related to
the release of water from the nanocontainers, whereas the
second step denotes the thermal decomposition of all organic
compounds, including ds, tocopherol and BTZ043. The thermal
remnant with a solid residue of only 25 wt-% was identified as
mixture of Ca3(PO4)2 and Ca10(PO4)6O (Figure 3d). These finding
reflects the low thickness of the Ca3(PO4)2 sphere wall in
comparison to the total volume of the BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers.
To determine the concentration of the encapsulated BTZ043
in BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers, UV-VIS spec-
troscopy was applied (Figure 4). To this concern, a calibration
curve of BTZ043 dissolved in ds-stabilized BTZ043/Toc micro-
emulsions at known concentrations was measured (Figure 4b).
This calibration curve shows an almost ideal linear dependence
between absorbance and BTZ043 concentration in a range of
0–40 μg/mL. Using the Lambert-Beer equation is therefore
appropriate to determine the BTZ043 concentration in the
nanocontainers. Since the measurements were performed in a
reflecting sphere (Ulbricht sphere), the scattering of the nano-
containers is not an issue. As a result of the photometrical
quantification, the as-prepared suspensions contain the nano-
containers with a concentration of c(NP)=1 mg/mL and BTZ043
with a concentration of c(BTZ043)=30.5 μg/mL. This finding is
in good agreement with the results from elemental analysis
(3.2 mg BTZ043 per 100 mg of the nanocontainers).
2.3. Structure of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2
nanocontainers
The structure of the as-prepared BTZ043/Toc@Ca(ds)2@Ca3(PO4)2
nanocontainers was characterized based on electron micro-
scopy, including SEM, scanning transmission electron micro-
scopy (STEM) and high-resolution transmission electron micro-
scopy (HRTEM). Accordingly, SEM shows a mean diameter of
28�8 nm (Figure 5a,b), which is well in agreement with the
mean hydrodynamic diameter obtained by DLS analysis (30�
13 nm, Figure 2b). In addition to size characterization based on
a statistically relevant great number of nanocontainers via DLS
and SEM, STEM images of nanocontainers at high magnification
Figure 2. Colloidal properties of the BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers: a) Zeta potential in relation to the different steps of the synthesis; b)
Particle size distribution according to DLS and SEM.
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confirm the outer particle diameter and–even more important–
the presence of the inner cavity in the BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers (Figure 5c,d). Accordingly, the
significantly lower electron absorption validates the inner cavity
with a diameter of 18�7 nm and the surrounding sphere wall
with a thickness of about 4�1 nm (Figure 5d).
In addition to SEM, it was of course intended to perform
TEM analysis of the nanocontainers. However, TEM analysis of
the as-prepared BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers
failed since the nanoparticles were completely destroyed in the
electron beam within few seconds. This finding can be
employed by using the acceleration voltage applied by SEM
(20 kV) and TEM (200 kV) to estimate the stability of the
nanocontainers. Due to the significantly higher kinetic energy
of the electrons as well as the resulting warming and charging,
the nanocontainers are stable enough under SEM conditions
but not under TEM conditions. Taking the non-conducting
nature of the nanocontainers, 28�8 nm in diameter, and the
presence of an inorganic shell with a thickness of only 4�1 nm
and 18�7 nm of a decomposable organic inner cavity into
account, the rapid decomposition of the BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers under TEM conditions is not a
surprise.
To perform TEM analysis, we have modified the synthesis in
order to realize in principle identical nanocontainers, however,
with a larger diameter and a thicker sphere wall. In this regard,
specifically the SDS :Ca(Ac)2 :Na(H2PO4) ratio was modified to
1.0 :20.4 : 10.5 with significantly higher amounts of calcium and
phosphate (instead of SDS :Ca(Ac)2 :Na2(HPO4)=1.0 : 5.3 :2.6 for
the aforementioned small-sized nanocontainers). These modi-
fied, larger BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers were
then examined by TEM and energy-dispersive X-ray spectro-
scopy (EDXS) (Figures 6,7). Whereas the diameter of the inner
cavity of the modified BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nano-
containers increased only slightly to 39�15 nm, the thickness
of the Ca3(PO4)2 wall was significantly increased to 27�7 nm
(Figures 6a). As a consequence, the outer diameter of the
modified BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers was
Figure 3. Chemical composition of the BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers: a) XRD of as-prepared sample (reference: ICDD-No. 00-064-0738:
Ca10(PO4)6(OH)2); b) FT-IR of as-prepared sample with ds, tocopherol and BTZ043 as references; c) TG of as-prepared sample; d) XRD of thermal remnant after
TG analysis (references: ICDD-No. 00–055-0898: Ca3(PO4)2; ICDD-No. 01-089-6489: Ca10(PO4)6O).
Full Paper
10ChemNanoMat 2021, 7, 7–16 www.chemnanomat.org © 2020 The Authors. ChemNanoMat published by Wiley-VCH GmbH
Wiley VCH Montag, 04.01.2021


























































Figure 4. Photometrical analysis of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers: a) UV-VIS spectra of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 suspension (samples)
and Toc@Ca(ds)2@Ca3(PO4)2 suspension (reference) as well as difference of both curves (suspensions with c(nanocontainers)=1.0 mg/mL); b) UV-VIS calibration
curve for BTZ (ds-stabilized BTZ043/Toc microemulsions) with absorbance measured at λ=347 nm (pink dots represent the measured values; black line
represents the linear fitting function).
Figure 5. Electron microscopic characterization of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers: a+b) SEM images at different levels of magnification; c+d)
STEM images at different levels of magnification.
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increased to 80�20 nm. In addition, the size distribution
became broader as compared to the original small-sized nano-
containers.
EDXS element mappings of the modified, larger BTZ043/
Toc@Ca(ds)2@Ca3(PO4)2 show a homogenous distribution of
calcium, phosphorus and oxygen all over the nanocontainers
(Figures 6). The presence of an inner cavity with an outer
Ca3(PO4)2 shell was confirmed by HAADF-STEM images (Fig-
ure 6) as well as by the EDXS element mappings (especially in
the case of calcium, Figure 6d). Here, it needs to be noticed that
element mappings of fluorine and sulfur, potentially indicating
BTZ043 and ds, did not result in reliable intensities in regard of
the significance of the measurement. This can be ascribed to
the low concentration in the liquid phase in comparison to the
significantly higher density of the respective elements per
volume in the solid Ca3(PO4)2 wall. The presence of the inner
cavity is even more obvious when performing EDXS line scans
(Figures 7a). Determining the concentration of Ca, P and O
along the orange line on the HAADF-STEM image shows a
characteristic dip in the center of the nanocontainer (Figur-
es 7b). This lower concentration of Ca, P and O indicates the
inner cavity of the nanocontainer since the electron beam only
passes through bottom and ceiling of the nanocontainer. In
contrast, EDXS line scans point to a maximum concentration of
Ca, P and O if the electron beam cuts through the side of the
nanocontainer (Figures 7b). Altogether, HRTEM and EDXS analy-
sis of the modified, larger BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 clearly
point to the presence of nanocontainers with an inner cavity. In
terms of biomedical use, the small-sized nanocontainers with
an outer diameter of 28�8 nm are of course much more
interesting (Figure 5).
Figure 6. Modified (larger) BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers: a) STEM overview image; b) DLS of aqueous suspension; c) HAADF-STEM image of
selected nanocontainer; d–e) EDXS of the nanocontainer on HAADF-STEM image (d) with element mappings of Ca (d), P (e), O (f).
Figure 7. EDXS line scan of modified (larger) BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers: a) HAADF-STEM image; b) EDXS line scan of nanocontainer on
HAADF-STEM image (a) along the orange line indicating the element distribution of Ca, P, O.
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2.4. Antibiotic activity of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2
nanocontainers
To verify the feasibility of our nanocontainer concept as a
proof-of-the-concept, murine bone marrow derived macro-
phages (BMMO) infected with M.tb. were used to assess anti-
mycobacterial activity by determining colony forming units
(CFU) (Figure 8a). Anti-mycobacterial activities were assessed in
BMMO infected with M.tb. for 2 hours and subsequently
incubated with the compounds at 37 °C/7.5% CO2 atmosphere
for 48 and 72 hours before cells were lysed. Cells were treated
with either BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers in
aqueous suspension, BTZ alone (stock solution pre-dissolved in
DMF, positive control), empty Toc@Ca(ds)2@Ca3(PO4)2 nano-
containers that did not contain BTZ043 (aqueous suspension,
negative control) or were left non-treated (negative control)
(Figure 8b,c). The dilutions as indicated in Figures 8b and c
were adjusted to BTZ043 concentration equivalents.
Toc@Ca(ds)2@Ca3(PO4)2 reference nanocontainers did not
affect mycobacterial growth, which was similar to non-treated
cells as indicated by similar numbers of colony forming units
(CFU). The viability of the macrophage monolayers was neither
affected by empty nor by BTZ043-free nanocontainers, which
indicates that the nanocontainers as such–including tocopherol,
ds as the surfactant, and Ca3(PO4)2 as the inorganic shell–did
not cause any observable cytotoxic effects even in infected cells
(data not shown). However, BTZ043/Toc@Ca(ds)2@Ca3(PO4)2
nanocontainers show anti-mycobacterial efficacy at 1 and
0.1 μg/ml concentrations comparable to free BTZ043 (solution
in DMF, Figure 8b,c). Thus, BTZ043 has the same antibiotic
activity at comparable concentrations although encapsulated in
nanocontainers. Since the uptake into infected cells is a much
less complex mechanism in cell cultures in vitro as compared to
the situation in vivo, where drugs additionally need to enter the
infectious sites, i. e., by crossing the granuloma barrier, this
result is highly promising as the nanocontainers may exhibit
activity identical to the dissolved, free drug. In vivo drug efficacy
studies using M. tb.-infected mice, however, require high safety
levels and complex experimental set-ups (broad range of doses,
Figure 8. Antibiotic activity of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers against intracellular M. tb.: a) Schematic drawing of antibiotic activity tests in
M.tb. H37Rv infected macrophages by determining colony forming units (CFU). Data shown represent the means + /  standard deviations from three technical
triplicates representing three independent equivalent biological replica experiments; b+c) Assessment of CFU for the nanocontainers in BMMO infected with
M. tb. for 2 h and subsequent incubation for b) 48 hours and c) 72 hours with solution of BTZ in DMF (positive control), Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers
(negative control) and non-treated intracellular M. tb. (negative control).
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adjustment of various host parameters), which is beyond this
in vitro proof-of-concept study.
3. Conclusions
BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers filled with the
lipophilic anti-tuberculosis drug 1,3-benzothiazin-4-one-043
(BTZ043) were prepared via a microemulsion strategy. The
microemulsion was established with water as the dispersant
phase, tocopherol as the lipophilic droplet phase and dodecyl-
sulfate (ds) as anionic surfactant. Tocopherol (vitamin E) was
chosen as biocompatible oil phase and used to dissolve
BTZ043. The micellar system was stabilized first by addition of
Ca2+, which coordinates to the sulfate groups of ds and thereby
reduces the thermal motion of the surfactant. Thereafter,
Na2(HPO4) was slowly added to allow the formation of a
Ca3(PO4)2 shell around the former micellar droplet, which results
in BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers.
The composition of the nanocontainers was validated by
different analytical tools (XRD, FT-IR, UV-Vis, Zeta potential
analysis, thermogravimetry, elemental analysis, electron micro-
scopy). Optical spectroscopy as well as elemental analysis
confirm a BTZ043 load of 3.1 mg BTZ043 per 100 mg of the
nanocontainers. Electron microscopy (SEM, TEM) and electron
spectroscopy (EDXS) validate the nanocontainer structure with
an outer diameter of 28�8 nm, a sphere wall of 4�1 nm and
an inner cavity of 18�7 nm. Upon variation of the SDS :Ca
(Ac)2 :Na2(HPO4) ratio, the size can be modified resulting in
larger nanocontainers with an outer diameter of 80�20 nm, a
wall thickness of 27�7 nm and an inner cavity of 39�15 nm.
First in vitro tests in M.tb.-infected macrophages treated
with BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers in compar-
ison to BTZ (positive control) and BTZ-free nanocontainers
(negative control) indicate the novel BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers to be as active as BTZ043 alone.
On the one hand, this validates the feasibility of the nano-
container concept, and on the other hand, this indicates the




General aspects. Sodium dodecylsulfate (SDS, �99.0%, Sigma-
Aldrich, Germany), n-butanol (>99.5%, Riedel-de-Haën, Germany),
α-tocopherol (97%, ABCR, Germany), Na(H2PO4)×H2O (99.5%,
Riedel-de-Haën), Na2(HPO4)×2H2O (99%, Riedel-de-Haën), disodium
citrate (99%, Sigma-Aldrich), citric acid (99.5%, Sigma-Aldrich),
calcium acetate (>99%, Sigma-Aldrich), and benzothiazinone-043
(99.66%, MedChemExpress, Germany) were used as purchased.
Formation of the microemulsion. A colloidally stable oil-in-water
microemulsion (o/w-ME) was established by mixing 2.5 mL
(140 mmol) of demineralized water as the polar dispersant phase,
0.4 mL (0.38 g, 0.88 mmol) of tocopherol (Toc) as the lipophilic
droplet phase, 700 mg (2.43 mmol) of sodium dodecylsulfate (SDS)
as the surfactant and 0.45 mL (0.36 g, 4.91 mmol) of n-butanol as
the co-surfactant. It needs to be noticed that the much more
common co-surfactants n-pentanol and n-hexanol in combination
with tocopherol only result in highly viscous gelatinous phases. In
contrast, microemulsions with n-butanol and a SDS :n-butanol ratio
around 1 :2 turned out highly stable. Thus, a yellow, transparent
microemulsion was obtained. Thereafter, 27.2 mg BTZ043 were
dissolved in the microemulsion, resulting in a color change from
yellow to red. Thereafter, 0.8 mL of the as-prepared microemulsion,
containing 140 mg (0.48 mmol, 1 eq) of SDS, 5.4 mg of BTZ043 and
0.08 mL (0.08 g, 0.17 mmol) of Toc were diluted with demineralized
water to a total volume of 5 mL and allowed to equilibrate for
30 min.
Formation of BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers. A sol-
ution of 400 mg (2.53 mmol, 5.3 eq) of calcium acetate and 30 mg
(0.16 mmol) of citric acid in 50 mL of water was adjusted to pH 10
upon addition of 0.1 M NaOH. The aforementioned diluted micro-
emulsion was slowly added to this solution with a syringe pump
over a period of 30 min. The resulting reddish suspension was
stirred for 1 hour and then centrifuged (15,000 rpm, 15 min).
Thereafter, the nanocontainers were redispersed in 50 mL of
demineralized water and the pH of the suspension adjusted to
pH 10 upon addition of 0.1 M NaOH. Finally, a solution of 225 mg
(1.26 mmol, 2.62 eq) of Na2(HPO4) in 5 mL of demineralized water
was added via a syringe pump over a period of 30 min. The
resulting suspension was centrifuged (25,000 rpm, 15 min), redis-
persed in water and again centrifuged (25,000 rpm, 15 min). There-
after, the BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers can be
redispersed in 8.46 mM solution of disodium citrate or dried to
obtain powder samples.
Formation of the microemulsion to obtain larger nanocontainers. The
microemulsion was prepared as described above. Instead of 0.8 mL
of the as-prepared microemulsion, however, only 0.2 mL of the as-
prepared microemulsion, containing 35 mg (0.12 mmol, 1 eq) of
SDS, 1.35 mg of BTZ043 and 0.02 mL (0.02 g, 0.043 mmol) of Toc
were added to a solution of 225 mg (1.26 mmol, 10.3 eq) of Na
(H2PO4) and 30 mg (0.16 mmol) of citric acid in 50 mL of water.
Upon addition of 0.5 M NaOH the solution was adjusted to pH 6.1.
Thereafter, 338 mg (2.45 mmol, 20.4 eq) of Ca(Ac)2 in 5 mL of water
were added dropwise. The solution slowly turned to a colorless
turbid suspension. This suspension was stirred for additional
4 hours and then gradually heated to 80 °C within 3 hours.
Prolonged stirring and slow heating support dehydration and
densification of the Ca3(PO4)2 shell, which is indicated by a slow
decrease of the pH value from 6.1 to 5.1 according to the following
reaction: 3Ca2+ +2[H2PO4]
  !Ca3(PO4)2+4H
+. Finally, the nanocon-
tainers were purified by centrifugation, followed by redispersion in
and centrifugation from demineralized water, which was performed
twice to remove all salts and residual starting materials. Thereafter,
the nanocontainers can be redispersed in water or dried to obtain
powder samples.
Analytical equipment
Scanning electron microscopy (SEM). Scanning electron microscopy
(SEM) was carried out with a Zeiss Supra 40 VP microscope (Zeiss,
Germany), equipped with a Schottky field emitter (2.0 nm reso-
lution). To this concern, diluted aqueous suspensions of the
BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers were deposited on
silicon wafers and left for drying overnight. The acceleration voltage
was in the range of 5–13 kV and the working distance was 2–3 mm.
Average particle diameters were calculated by statistical evaluation
of at least 150 nanoparticles (ImageJ 1.47v software).
Full Paper
14ChemNanoMat 2021, 7, 7–16 www.chemnanomat.org © 2020 The Authors. ChemNanoMat published by Wiley-VCH GmbH
Wiley VCH Montag, 04.01.2021


























































Transmission electron microscopy (TEM). Transmission electron
microscopy (TEM) and high-angle annular dark-field scanning
transmission electron microscopy (HAADF-STEM) were conducted
with a FEI Osiris microscope at 200 kV (FEI, The Netherlands). TEM
samples were prepared by evaporating aqueous suspensions of the
BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers on amorphous car-
bon (Lacey-)film suspended on copper grids. Average particle
diameters were calculated by statistical evaluation of at least 150
nanoparticles (ImageJ 1.47v software).
Energy-dispersive X-ray (EDX) spectroscopy. High-resolution EDXS
was performed to analyze the chemical composition of single
BTZ043/Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers. The spectra were
obtained at 200 kV electron energy with a FEI Osiris microscope
that was equipped with a Bruker Quantax system (XFlash detector,
Bruker, Germany). EDX spectra were quantified with the FEI
software package “TEM imaging and analysis” (TIA). Using TIA,
element concentrations were calculated on the basis of a refined
Kramers’ law model that includes corrections for detector absorp-
tion and background subtraction. Standardless quantification, i. e.
by means of theoretical sensitivity factors, without thickness
correction was applied. EDX spectra were taken in the STEM mode
with a probe diameter of 0.5 nm. Using a focused electron probe,
EDXS area scans were performed to obtain average compositions of
larger sample regions. The EDX spectra were acquired by continu-
ously scanning the electron probe in the pre-defined region.
Dynamic light scattering (DLS). DLS was used to determine the
hydrodynamic diameter of the as-prepared BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers in the suspensions. Studies were
conducted at room temperature in glass or polystyrene cuvettes
applying a Nanosizer ZS (Malvern Instruments, United Kingdom).
X-ray powder diffraction (XRD). X-ray powder diffraction (XRD) was
performed with a Stoe STADI-MP diffractometer (Stoe, Germany)
operating with Ge-monochromatized Cu  Kα-radiation (λ=
1.54178 Å) and Debye-Scherrer geometry. The dried BTZ043/
Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers nanocontainers were fixed
between Scotch tape and acetate paper and measured between
  69° and +69° of two-theta.
Fourier-transformed infrared spectroscopy (FT-IR). Fourier-trans-
formed infrared spectroscopy (FT-IR) was performed on a Bruker
Vertex 70 FT-IR spectrometer (Bruker, Germany). All BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers samples were pestled and diluted
with KBr (3 mg of sample per 300 mg of KBr) and pressed to pellets.
Elemental analysis (C/H/N/S analysis). Elemental analysis (C/H/N/S
analysis) was performed via thermal combustion with an Elementar
Vario Microcube device (Elementar, Germany) at a temperature of
about 1100 °C.
Optical spectroscopy (UV-Vis spectroscopy). UV-Vis spectroscopy was
used to quantify the amount of BTZ in the respective BTZ043/
Toc@Ca(ds)2@Ca3(PO4)2 nanocontainers according to the Kubelka-
Munk formalism. The respective concentrations were quantified in
comparison to reference solutions with known concentration by
applying a calibration curve. UV-VIS spectra were recorded with an
UV2700 from Shimadzu (Japan). Nanoparticle suspensions were
measured in quartz glass cells (Starna, type Q, 170–2700 nm,
spectral quality 6) in an integrating sphere in diffuse transmission
geometry against the corresponding pure solvent as a reference.
In vitro studies
M. tuberculosis-infected macrophages. Bone marrow (BM) was
flushed out of the femur and tibia of C57BL/6 mice using ice-cold
complete DMEM (high glucose DMEM Dulbecco’s modified eagle
medium supplemented with 10% FCS, 10 mM HEPES, 2 mM L-
glutamine, 50 ng/mL M–CSF; Sigma-Aldrich). Single cell suspensions
were cultured for 7 days at 37 °C with 5% CO2. At day 7,
differentiated macrophages were harvested by flushing with ice-
cold PBS, counted, adjusted to 106 cells/mL, seeded in 48-well cell
culture plates (Sarstedt, Germany), and used for further experi-
ments.
M. tuberculosis H37Rv was harvested by centrifugation at 1000×g
for 10 min. The bacterial pellet was resuspended in DMEM and
centrifuged for another 10 min at 1500×g. The supernatant was
exchanged by fresh medium and flushed 4-times through a 23G
needle (BD Pharmingen, San Diego, USA), adjusted against cell
culture media to an optical density (OD) at 600 nm of 0.5, and used
1 in 10 diluted in cell culture medium for infection of BMMO. Cells
were infected for 2 h at 37 °C, 7.5% CO2 with M. tuberculosis. After
washing, the cells were further incubated with BTZ043/Toc@Ca
(ds)2@Ca3(PO4)2 nanocontainers and the respective control com-
pounds. After 48 and 72 h of incubation, BMMO were lysed in water
containing 01% bovine albumin and 0.1% Tween80. Lysates were
diluted and plated onto 7H11 agar plates. After 3 weeks of
incubation at 37 °C, colony forming units were counted (see
schematic drawing in Figure 8a).
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